---
layout: default
title: Zinc Gluconate
parent: 僅模型預測 (L5)
nav_order: 698
evidence_level: L5
indication_count: 10
---

# Zinc Gluconate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the evidence pack as provided. Note: the JSON key is `taiwan_regulatory` and all data-gap remediation sources point to **TFDA** (Taiwan), not NPRA/Malaysia — so I've labeled the market section "Taiwan" to match the actual data source rather than the template's placeholder text.

---

# Zinc Gluconate: From Unspecified Original Indication to Anemia of Prematurity

## One-Sentence Summary

> Zinc gluconate's original approved indication is not documented in this evidence pack — Taiwan regulatory records show 136 active market authorizations, but no license-level indication text was returned.
> The TxGNN model predicts possible efficacy for **Anemia of Prematurity** (score 99.94%),
> but this prediction currently has **no supporting clinical trials or published literature** — it rests entirely on the model's internal score.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not documented in evidence pack (license indication text unavailable) |
| Predicted New Indication | Anemia of Prematurity |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Taiwan Market Status | ✓ Marketed (已上市) |
| Number of Registrations | 136 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for zinc gluconate is not available in this evidence pack (flagged as a High-severity data gap, DG002 — remediation: query DrugBank API). Based on general pharmacology, zinc is a cofactor for numerous metalloenzymes, including several involved in hematopoiesis, which is the basis of the model's proposed mechanistic link.

The repurposing rationale attached to this specific prediction states: *"Zinc is a hematopoietic cofactor and could theoretically influence erythropoiesis, but there is currently no direct evidence supporting zinc gluconate for anemia of prematurity."* This is a plausible but entirely theoretical connection — no original indication data was available to compare against, and no clinical or preclinical evidence has yet been retrieved to test the hypothesis.

Given the absence of both original-indication context and MOA detail, this prediction should be treated as a hypothesis-generation signal only, not as a mechanistically substantiated candidate.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Taiwan Market Information

Taiwan regulatory records confirm zinc gluconate is marketed with **136 active licenses**, but license-level details (authorization number, product name, dosage form, approved indication text) were not returned in this evidence pack — all fields in the license array are empty. This is a data-completeness issue in the source extraction, not an indication that the drug lacks approved indications.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: Warnings, contraindications, and DDI data are flagged as a **Blocking** data gap — DG001 — meaning this candidate cannot yet enter S1 safety evaluation. Remediation requires downloading and parsing the TFDA label PDF.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (Anemia of Prematurity) is supported only by the TxGNN model score with zero clinical trials or literature (Evidence Level L5). Compounding this, a **Blocking** drug-level data gap (missing TFDA label warnings/contraindications) prevents any safety pre-screening. Reviewing the other top-10 predictions for this drug (e.g., "injury," "cell proliferation disorder," "segmental odontomaxillary dysplasia") shows they are either overly broad ontology labels with mostly irrelevant retrieved evidence, or have no evidence at all — none currently rise above L5/L4 with directly relevant, on-target data.

**To proceed, the following is needed:**
- TFDA label PDF (warnings, contraindications) — DG001, blocking, required before any S1 safety evaluation
- DrugBank MOA query — DG002, needed to properly assess mechanistic plausibility
- Original indication text from Taiwan license records (currently empty in the evidence pack)
- Targeted literature/clinical trial search specific to "anemia of prematurity" + zinc, since the current evidence pack returned none
- Re-evaluation once L5 candidates accumulate at least preclinical (L4) or observational (L3) evidence directly on-target
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

